drugset / Trial / NCT01380366

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366

NaSingle-groupOpen-labelTreatment

Summary

Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)"). Zorbtive® is an FDA approved recombinant human growth hormone (rHGH). The investigators want to see if taking this medication improves small bowel function by helping it to take in food, nutrients, vitamins and minerals. The investigators also believe that if the small bowel is absorbing food and nutrients better, liver function will improve as well. Therefore, liver function will also be monitored during the course of the study by performing blood tests.

Timeline

Start
2006-10
Primary completion
2011-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.1 mg/kg Subcutaneous

Indications